Amnovis reaches milestone in the production of 3D-printed titanium implants

Belgian company Amnovis has produced over 50,000 titanium implants since 2021 using an innovative, heat treatment-free 3D printing process. This technology optimizes the production of implants for spinal, orthopedic and cranio-maxillofacial (CMF) applications by enabling faster manufacturing and lower production costs.

Traditionally, 3D printed titanium implants require post heat treatment to improve the material properties. However, Amnovis has developed a proprietary process that does not require this additional treatment.

Ruben Wauthle, CEO and Co-founder of Amnovis, explained, “We developed and validated a proprietary process for pure titanium that requires no heat treatment. This unique process allows us to deliver faster, more cost-effective solutions for our customers while maintaining the highest quality standards.”

This innovation accelerates market entry for original equipment manufacturers (OEMs) in particular, which strengthens Amnovis’ competitive advantage. The partner company privelop-spine also benefits from this technology.

Henning Kloss, CEO of privelop-spine, shared, “Since partnering with Amnovis, we’ve been impressed by their production quality and specialist expertise. Surgeons consistently praise the detailed resolution, look, and feel of our implant structures, while distributors and users appreciate the reliability and punctual delivery. Amnovis’ heat treatment-free titanium process has significantly streamlined our production, reducing time and costs. Their production capacity and reliability have made a substantial contribution to our collaboration with large customers, helping us bring products to market faster.”

In addition to the heat treatment-free process, Amnovis continues to offer traditional titanium 3D printing services, including the processing of Ti-6Al-4V Grade 23 with heat treatments such as Hot Isostatic Pressing (HIP). This gives OEMs the flexibility to choose the right process for their specific requirements.

Amnovis will showcase its capabilities at the NASS Annual Meeting in Chicago from September 25-27, 2024 and plans to further expand its production capabilities to meet the increasing demand in the medical device industry.